BioSpace1h
ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
BioSpace2h
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but Neuropsychiatric Events Reported
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...
BioSpace2h
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study Following Earlier Flops
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...
BioSpace16h
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
BioSpace3h
Aligos Claims Mid-Stage Win in MASH, But Investors Are Skeptical
An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...